Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19624818 | 1.00 | BTK (0.51) | BTKGPR119CHEK2HPGDKDM4E | |
| SCHEMBL19544682 | 0.95 | BTK (0.48) | BTKGPR119CHEK2HPGDKDM4E | |
| SCHEMBL19544905 | 0.94 | BTK (0.49) | BTKGPR119CHEK2 | |
| SCHEMBL19624659 | 0.94 | BTK (0.47) | BTKGPR119CHEK2HPGDKDM4E | |
| SCHEMBL19544647 | 0.91 | BTK (0.55) | BTK | |
| SCHEMBL19544659 | 0.91 | BTK (0.55) | BTK | |
| SCHEMBL25060355 | 0.90 | BTK (0.48) | BTKGPR119CHEK2ALDH1A1 | |
| SCHEMBL19544304 | 0.90 | BTK (0.48) | BTKGPR119CHEK2ALDH1A1 | |
| SCHEMBL19624846 | 0.90 | CHEK2 (0.45) | BTKGPR119CHEK2HPGDKDM4E | |
| SCHEMBL19544728 | 0.89 | BTK (0.54) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246317-B1 | BTK INHIBITOR | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2023-02-22 | — | — | EP | disclosed |
| US-10662174-B2 | BTK inhibitor | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-05-26 | — | — | US | disclosed |
| EP-3246317-A1 | BTK INHIBITOR | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-11-22 | — | — | EP | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662174-B2 | BTK inhibitor | BTK, SYK, LYN | BTK 1/4885GPR119 2179/4885CHEK2 333/4885 |
| US-20170313683-A1 | BTK INHIBITOR | BTK, SYK, LYN | BTK 1/4885GPR119 2179/4885CHEK2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.